Gilead's (GILD) Viread Approved for Chronic Hepatitis B in Adults
More News related to GILD
- Gilead Sciences to Present at Two Upcoming Investor Conferences
- Gilead Sciences Announces Notification of ANDA Filing for Truvada
- David Moenning's Daily State of the Markets: 11/12
- Notable Analyst Rating Changes 11/12: BBBY, PAG, ROK Upgraded; EGLE, FMCN, BRCM Downgraded
- Needham & Co Initiates Coverage on Gilead Sciences (GILD), Represents Core Holding
More News related to FDA
- After-Hours Movers 12/01: Palm (PALM), Mosaic (MOS) Lower on Guidance
- Trading Radar for 12/02: Staples (SPLS), Marvell (MRVL), Solarfun (SOLF), Beazer (BZH), Sears (SHLD) Report; Auto/Truck Sales for Nov. Due
- Unusual 11 Mid-Day Movers 12/01: MNT, PSUN, ALD, PGI Higher; PPC, MTL, EXM, LIZ Lower
- Notable Analyst Rating Changes 12/01: PRU, TOL, DO, WLP Upgraded; SNP, LTD, COG, ADM Downgraded
- Notable Mergers and Acquisitions of the Day 12/01: JNJ/MNT, AIG, F, FFH
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the FDA has granted marketing approval for Viread for the treatment of chronic hepatitis B, a serious liver disease caused by the hepatitis B virus.
Chronic hepatitis B is the leading cause of liver cancer worldwide and affects an estimated two million individuals in the United States.
Related Categories
FDAStocks Mentioned
-2.33Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
